Tongqing Zhou

List of Publications by Year
in descending order

140 papers	22,631 citations	19657 61 h-index	11607 135 g-index
166 all docs	166 docs citations	166 times ranked	17496 citing authors

#	Article	IF	Citations
1	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 2010, 329, 856-861.	12.6	1,600
2	Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature, 2020, 584, 450-456.	27.8	1,337
3	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. Science, 2010, 329, 811-817.	12.6	1,050
4	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496, 469-476.	27.8	961
5	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	27.0	936
6	Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. Science, 2013, 342, 592-598.	12.6	797
7	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature, 2011, 480, 336-343.	27.8	794
8	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science, 2011, 333, 1593-1602.	12.6	788
9	Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature, 2007, 445, 732-737.	27.8	715
10	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014, 514, 455-461.	27.8	702
11	Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science, 2013, 340, 1113-1117.	12.6	656
12	Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization. Cell, 2013, 153, 126-138.	28.9	478
13	Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host and Microbe, 2021, 29, 819-833.e7.	11.0	444
14	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell, 2016, 165, 813-826.	28.9	379
15	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 2022, 386, 1088-1091.	27.0	338
16	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nature Structural and Molecular Biology, 2015, 22, 522-531.	8.2	333
17	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. Immunity, 2013, 39, 245-258.	14.3	332
18	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host and Microbe, 2020, 28, 867-879.e5.	11.0	316

#	Article	IF	Citations
19	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science, 2016, 352, 828-833.	12.6	310
20	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	28.9	305
21	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell, 2016, 165, 449-463.	28.9	305
22	Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1166-1171.	7.1	304
23	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity, 2016, 45, 1108-1121.	14.3	304
24	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports, 2022, 39, 110812.	6.4	287
25	Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120. Science, 2009, 326, 1123-1127.	12.6	271
26	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	28.9	266
27	Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communications, 2015, 6, 7712.	12.8	258
28	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine, 2018, 24, 857-867.	30.7	256
29	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i>. Journal of Virology, 2014, 88, 12669-12682.	3.4	248
30	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	28.9	228
31	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell, 2015, 161, 470-485.	28.9	226
32	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science, 2017, 358, 85-90.	12.6	225
33	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5663-5668.	7.1	222
34	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. Science, 2013, 340, 751-756.	12.6	213
35	Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1. Journal of Virology, 2010, 84, 8098-8110.	3.4	209
36	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science, 2021, 373, .	12.6	174

#	Article	IF	Citations
37	Platelet-derived growth factor-Î± receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. Nature Microbiology, 2016, 1, 16082.	13.3	170
38	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nature Structural and Molecular Biology, 2016, 23, 81-90.	8.2	162
39	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Reports, 2017, 19, 719-732.	6.4	160
40	Associating HIV-1 envelope glycoprotein structures with states on theÂvirus observed by smFRET. Nature, 2019, 568, 415-419.	27.8	156
41	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. Journal of Virology, 2018, 92, .	3.4	155
42	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature, 2021, 595, 278-282.	27.8	154
43	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. Cell Host and Microbe, 2020, 28, 880-891.e8.	11.0	153
44	Structures of the Multidrug Transporter P-glycoprotein Reveal Asymmetric ATP Binding and the Mechanism of Polyspecificity. Journal of Biological Chemistry, 2017, 292, 446-461.	3.4	152
45	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science, 2022, 376, eabn8897.	12.6	119
46	Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site. PLoS Pathogens, 2009, 5, e1000445.	4.7	113
47	Crystal Structures of GII.10 and GII.12 Norovirus Protruding Domains in Complex with Histo-Blood Group Antigens Reveal Details for a Potential Site of Vulnerability. Journal of Virology, 2011, 85, 6687-6701.	3.4	113
48	PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4. Journal of Virology, 2012, 86, 4394-4403.	3.4	109
49	Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nature Communications, 2015, 6, 8223.	12.8	106
50	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. Cell, 2019, 178, 567-584.e19.	28.9	106
51	De novo identification of VRC01 class HIV-1â€"neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4088-97.	7.1	105
52	Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. Nature Structural and Molecular Biology, 2017, 24, 370-378.	8.2	94
53	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine, 2022, 14, eabj7125.	12.4	93
54	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Scientific Reports, 2020, 10, 18149.	3.3	90

#	Article	IF	Citations
55	Activation and lysis of human CD4 cells latently infected with HIV-1. Nature Communications, 2015, 6, 8447.	12.8	88
56	Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment. Journal of Virology, 2009, 83, 10892-10907.	3.4	86
57	Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1. Journal of Molecular Biology, 2017, 429, 930-947.	4.2	82
58	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. Journal of Virology, 2017, 91, .	3.4	81
59	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13.	14.3	77
60	Enhancing Protein Crystallization through Precipitant Synergy. Structure, 2003, 11, 1061-1070.	3.3	75
61	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1â€“4. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12265-12270.	7.1	70
62	Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. Cell Reports, 2017, 21, 2992-3002.	6.4	69
63	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. Structure, 2019, 27, 196-206.e6.	3.3	69
64	Tryptophan Fluorescence Reports Nucleotide-induced Conformational Changes in a Domain of the ArsA ATPase. Journal of Biological Chemistry, 1997, 272, 19731-19737.	3.4	67
65	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. Immunity, 2018, 48, 500-513.e6.	14.3	66
66	Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains. Journal of Virology, 2013, 87, 10047-10058.	3.4	64
67	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Reports, 2020, 33, 108322.	6.4	59
68	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	4.7	56
69	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	56
70	Subnanometer structures of HIV-1 envelope trimers on aldrithiol-2-inactivated virus particles. Nature Structural and Molecular Biology, 2020, 27, 726-734.	8.2	55
71	Mechanism of the ArsA ATPase. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1461, 207-215.	2.6	53
72	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathogens, 2016, 12, e1005537.	4.7	51

#	Article	IF	Citations
73	Transplanting Supersites of HIV-1 Vulnerability. PLoS ONE, 2014, 9, e99881.	2.5	51
74	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. MBio, 2022, 13, e0322721.	4.1	48
75	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. Journal of Virology, 2009, 83, 5077-5086.	3.4	43
76	Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine. Science Immunology, 2019, 4, .	11.9	40
77	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature Immunology, 2021, 22, 1503-1514.	14.5	40
78	Conformational Changes in Four Regions of the Escherichia coli ArsA ATPase Link ATP Hydrolysis to Ion Translocation. Journal of Biological Chemistry, 2001, 276, 30414-30422.	3.4	38
79	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS ONE, 2015, 10, e0128779.	2.5	38
80	Protection of calves by a prefusion-stabilized bovine RSV F vaccine. Npj Vaccines, 2017, 2, 7.	6.0	38
81	Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. Cell Reports, 2021, 37, 109771.	6.4	38
82	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathogens, 2018, 14, e1007431.	4.7	36
83	Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen. Scientific Reports, 2020, 10, 3032.	3.3	36
84	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. Immunity, 2021, 54, 324-339.e8.	14.3	36
85	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. Structure, 2016, 24, 1346-1357.	3.3	35
86	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. Journal of Virology, 2013, 87, 2294-2306.	3.4	34
87	High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. PLoS Pathogens, 2021, 17, e1009431.	4.7	34
88	Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains. Cell Reports, 2020, 33, 108432.	6.4	32
89	Interfacial metal and antibody recognition. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14575-14580.	7.1	29
90	Interaction of substrate and effector binding sites in the ArsA ATPase. Biochemistry, 1995, 34, 13622-13626.	2.5	28

#	Article	IF	Citations
91	Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Current Opinion in HIV and AIDS, 2013, 8, 382-392.	3.8	27
92	Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. PLoS ONE, 2016, 11, e0159709.	2.5	27
93	The ATPase Mechanism of ArsA, the Catalytic Subunit of the Arsenite Pump. Journal of Biological Chemistry, 1999, 274, 16153-16161.	3.4	26
94	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 2021, 9, 73.	4.4	24
95	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. Cell Host and Microbe, 2020, 27, 531-543.e6.	11.0	23
96	Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	21
97	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports, 2022, 38, 110199.	6.4	19
98	Asp45 Is a Mg2+ Ligand in the ArsA ATPase. Journal of Biological Chemistry, 1999, 274, 13854-13858.	3.4	18
99	Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. PLoS Pathogens, 2019, 15, e1007819.	4.7	18
100	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. PLoS ONE, 2022, 17, e0268767.	2.5	18
101	Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine. Advances in Experimental Medicine and Biology, 2018, 1075, 73-95.	1.6	17
102	A Kinetic Model for the Action of a Resistance Efflux Pump. Journal of Biological Chemistry, 2001, 276, 6378-6391.	3.4	16
103	A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nature Medicine, 2022, 28, 373-382.	30.7	16
104	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. Cell Reports, 2020, 32, 107981.	6.4	15
105	Unisite and Multisite Catalysis in the ArsA ATPase. Journal of Biological Chemistry, 2002, 277, 23815-23820.	3.4	13
106	Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation. Cell Reports, 2020, 32, 108088.	6.4	13
107	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine, 2022, 48, 101477.	7.1	13
108	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. Structure, 2022, 30, 1233-1244.e7.	3.3	13

#	Article	IF	Citations
109	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. Cell Reports, 2021, 35, 108937.	6.4	12
110	Eliminating antibody polyreactivity through addition of <i>N</i>â€linked glycosylation. Protein Science, 2015, 24, 1019-1030.	7.6	11
111	Blocking Î± ₄ Î² ₇ integrin delays viral rebound in SHIV _{SF162P3} -infected macaques treated with anti-HIV broadly neutralizing antibodies. Science Translational Medicine, 2021, 13, .	12.4	11
112	Antimonite regulation of the ATPase activity of ArsA, the catalytic subunit of the arsenical pump. Biochemical Journal, 2001, 360, 589-597.	3.7	10
113	Nonequivalence of the Nucleotide Binding Domains of the ArsA ATPase. Journal of Biological Chemistry, 2005, 280, 9921-9926.	3.4	10
114	Antimonite regulation of the ATPase activity of ArsA, the catalytic subunit of the arsenical pump. Biochemical Journal, 2001, 360, 589.	3.7	9
115	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. Journal of Biological Chemistry, 2021, 297, 101127.	3.4	9
116	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. Journal of Biological Chemistry, 2022, 298, 101819.	3.4	9
117	A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during InÂVivo Adaptation. Cell Reports, 2019, 27, 2593-2607.e5.	6.4	8
118	Spatiotemporal hierarchy in antibody recognition against transmitted HIV-1 envelope glycoprotein during natural infection. Retrovirology, 2016, 13, 12.	2.0	7
119	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. PLoS Pathogens, 2022, 18, e1010574.	4.7	6
120	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. Cell Reports, 2021, 37, 109922.	6.4	5
121	Structure of BMS-806, a Small-molecule HIV-1 Entry Inhibitor, Bound to BG505 SOSIP.664 HIV-1 Env Trimer. AIDS Research and Human Retroviruses, 2014, 30, A151-A151.	1.1	4
122	Removal of variable domain <i>N</i>-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. MAbs, 2020, 12, 1836719.	5.2	4
123	Antibody screening at reduced <scp>pH</scp> enables preferential selection of potently neutralizing antibodies targeting <scp>SARSâ€CoV</scp>â€2. AIChE Journal, 2021, 67, e17440.	3.6	4
124	Structural Biology and the Design of Effective Vaccines for HIV-1 and Other Viruses. , 2010, , 387-402.		4
125	Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. Structure, 2022, 30, 862-875.e4.	3.3	4
126	Crystallization and preliminary X-ray analysis of the catalytic subunit of the ATP-dependent arsenite pump encoded by the Escherichia coli plasmid R773. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 921-924.	2.5	3

#	Article	IF	Citations
127	Structural basis of HIV-1 gp120 conformational mobility. Acta Crystallographica Section A: Foundations and Advances, 2009, 65, s24-s24.	0.3	3
128	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. SSRN Electronic Journal, 2020, , 3639618.	0.4	3
129	Development of Neutralization Breadth against Diverse HIVâ€1 by Increasing Abâ€"Ag Interface on V2. Advanced Science, 2022, , 2200063.	11.2	3
130	Structural definition for a new modality of broad and potent antibody neutralization at the CD4-binding site on HIV-1 gp120. Retrovirology, 2012, 9, .	2.0	1
131	CD4-binding-Site Recognition by VH1-46 Germline-derived HIV-1 Neutralizers. AIDS Research and Human Retroviruses, 2014, 30, A120-A121.	1.1	1
132	Structural basis of LAIR1 targeting by polymorphic Plasmodium RIFINs. Nature Communications, 2021, 12, 4226.	12.8	1
133	Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses. SSRN Electronic Journal, 0, , .	0.4	1
134	Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite. Structure, 2022, , .	3.3	1
135	P09-13. Structure of HIV-1 gp41 interactive region: layered architecture and basis of conformational mobility. Retrovirology, 2009, 6, .	2.0	0
136	P09-05. Mechanism of HIV-1 resistance to a monoclonal antibody that effectively targets the site of CD4 attachment. Retrovirology, 2009, 6, .	2.0	0
137	Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies. Retrovirology, 2012, 9, .	2.0	0
138	Transient Protein Expression Facilitates X-ray Structural Studies of HIV-1. AIDS Research and Human Retroviruses, 2014, 30, A148-A149.	1.1	0
139	Conformational Changes in HIV-1 Env Trimer Induced by a Single CD4 as Revealed by Cryo-EM. Microscopy and Microanalysis, 2017, 23, 1190-1191.	0.4	0
140	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. Frontiers in Immunology, 2021, 12, 662909.	4.8	0